Making the Invisible Visible: Unlocking the Potential of Imaging Mass Spectrometry in Ovarian Carcinoma and Beyond
Discover new perspectives on the complexity of high‑grade serous ovarian cancer in our upcoming webinar, where cutting‑edge spatial multiomics meets real clinical impact. Learn how MALDI Imaging, combined with LMD‑based proteomics, spatial transcriptomics, and MALDI HiPLEX-IHC, is revealing previously unseen cellular subpopulations linked to treatment response and patient survival. This integrated strategy uncovers critical interactions between tumor and microenvironment that may drive chemoresistance and could pave the way for improved patient stratification and more personalized therapy. Join us to explore these groundbreaking results and see how spatial biology is transforming the future of cancer research.
Key Learning Objectives
- Learn how combining multimodal technologies can accelerate advanced biomarker discovery in oncology research
- Understand how MALDI Imaging adds valuable, untargeted spatial context to existing transcriptomics, proteomics, or imaging workflows
- Identify molecular subtypes and chemoresistance‑related interactions using spatial multiomics
Who Should Attend
- Researchers in oncology, spatial biology, and multiomics
- Clinical and translational scientists seeking new approaches for biomarker discovery and therapy prediction.
- Pharma and biotech professionals developing targeted therapies or exploring tumor–microenvironment interactions.
- Biologists working with transcriptomics, single‑cell, or microscopy methods who want to expand their capabilities into spatial and discover what MALDI Imaging can add
- Anyone interested in cutting‑edge imaging mass spectrometry and its applications in cancer research
Presenter: Dr. Oliver Klein, Group Leader, Berlin Institute of Health at Charité, Berlin, Germany
Dr. Oliver Klein received his master degree in Pharmaceutical/Chemical Engineering at the Beuth University of Applied Sciences and was subsequently focusing on the expression of protein domains to structure elucidation via NMR and mass spectrometry at the Leibniz Institute for Molecular Pharmacology (FMP) Berlin. Since 2007 he is working at the Charité, leading the Proteomics Unit at Berlin-Brandenburg Center for Regenerative Therapies (today BIH Center for Regenerative Therapies) since 2009. 2015 Dr. Klein earned his doctorate in the field of regenerative medicine, focusing on the detection of pathophysiological processes in tissue following cell therapy using Imaging MS and LC MS. From 2022 until today Dr. Oliver Klein leads the “Imaging mass spectrometry Unit at BIH” and is involved in several clinically driven projects including BMBFTR, DFG, EU and industry cooperations.
